UK Markets closed

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.37-0.75 (-12.24%)
At close: 04:47PM BST
Full screen
Previous close6.12
Open5.37
Bid0.00 x 0
Ask0.00 x 0
Day's range5.37 - 5.37
52-week range5.37 - 5.37
Volume2,950
Avg. volumeN/A
Market cap37.452M
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)-3.35
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update

    LYON, France, September 19, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its financial results for the six months ended June 30th, 2022.

  • Business Wire

    Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th

    LYON, France, September 15, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will release its first-half 2022 results on September 19th, 2022, post-market close.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of August 31st, 2022

    LYON, France, September 14, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inn